GlassScriptPhysician profile
Ferdinando A Andrade
NPI 1548608573
$8,742.95
in general payments reported to CMS, 2019-2025
50 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $332 · 2021: $3,037 · 2022: $1,712 · 2023: $904 · 2024: $1,033 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,850.36 | 2019-2024 | Bevespi Aerosphere, Airsupra, Farxiga |
| Amgen INC. | $1,206.55 | 2019-2025 | Repatha, Tepezza, Otezla |
| Abbvie INC. | $738.72 | 2021-2025 | Qulipta, Linzess, Viberzi |
| Novo Nordisk INC | $586.30 | 2019-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $444.79 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $391.45 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.17 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Otsuka America Pharmaceutical, INC. | $255.49 | 2022-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $241.58 | 2021 | |
| Pfizer INC. | $238.18 | 2019-2025 | |
| Lilly USA, LLC | $225.27 | 2020-2025 | Jardiance, Emgality, Mounjaro |
| Boston Scientific Corporation | $214.94 | 2021-2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $182.98 | 2019-2022 | |
| Abbott Laboratories | $155.64 | 2022-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.30 | 2019-2023 | Xifaxan |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ferdinando Andrade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.